|
Positive results for Sanofi/Regeneron's dupilumab in asthma
The Pharma Letter French pharma major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) have released positive results from the interim analysis of a dose-ranging Phase IIb study of dupilumab in adult patients with uncontrolled … |
View full post on asthma – Google News